A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
Status:
Completed
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple
ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy
adult subjects. Male or female subjects aged 18 to 50 years who fulfill the
inclusion/exclusion criteria will be enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Tetraphase Pharmaceuticals, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)